Which antipsychotic is associated with higher risk of death due to stroke or sudden cardiac death in patients with dementia?

Which antipsychotic is associated with higher risk of death due to stroke or sudden cardiac death in patients with dementia?

• A. Haloperidol
• B. Risperidone
• C. Olanzapine
• D. Quetiapine

Answer: (D)

In elderly patients with dementia, using antipsychotics to manage behavioral symptoms carries a real risk of death, primarily from cardiovascular events or stroke. This safety signal means that any such medication should be used only when truly necessary, for the shortest possible time, and at the lowest effective dose, with careful monitoring. Quetiapine, among the options listed, has been associated in some evidence and regulatory warnings with a higher risk of death from cerebrovascular events or sudden cardiac death in dementia patients. A key part of this risk is the drug’s potential to prolong the QT interval, which can predispose to serious arrhythmias, especially in older individuals who may have underlying heart disease, electrolyte abnormalities, or who are taking other QT-prolonging drugs. While all antipsychotics used in dementia carry safety concerns, this agent is the one highlighted for a greater signal of these cardiac- and stroke-related mortality risks in this population. If antipsychotic treatment is deemed necessary, prioritize nonpharmacologic approaches first, use the smallest effective dose for the shortest duration, and monitor cardiac status and electrolytes, avoiding combinations or conditions that further increase QT risk.

In elderly patients with dementia, using antipsychotics to manage behavioral symptoms carries a real risk of death, primarily from cardiovascular events or stroke. This safety signal means that any such medication should be used only when truly necessary, for the shortest possible time, and at the lowest effective dose, with careful monitoring.

Quetiapine, among the options listed, has been associated in some evidence and regulatory warnings with a higher risk of death from cerebrovascular events or sudden cardiac death in dementia patients. A key part of this risk is the drug’s potential to prolong the QT interval, which can predispose to serious arrhythmias, especially in older individuals who may have underlying heart disease, electrolyte abnormalities, or who are taking other QT-prolonging drugs. While all antipsychotics used in dementia carry safety concerns, this agent is the one highlighted for a greater signal of these cardiac- and stroke-related mortality risks in this population.

If antipsychotic treatment is deemed necessary, prioritize nonpharmacologic approaches first, use the smallest effective dose for the shortest duration, and monitor cardiac status and electrolytes, avoiding combinations or conditions that further increase QT risk.